Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Boehringer Ingelheim
Moodys
Dow
Queensland Health
Express Scripts
Chubb
Healthtrust
McKesson

Generated: May 25, 2018

DrugPatentWatch Database Preview

MOBIC Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Mobic patents expire, and what generic alternatives are available?

Mobic is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-one patent family members in twenty-four countries.

The generic ingredient in MOBIC is meloxicam. There are twenty-two drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the meloxicam profile page.
Summary for MOBIC
International Patents:31
US Patents:1
Applicants:1
NDAs:2
Suppliers / Packagers: 3
Bulk Api Vendors: 101
Patent Applications: 8,978
Formulation / Manufacturing:see details
DailyMed Link:MOBIC at DailyMed
Drug patent expirations by year for MOBIC
Synonyms for MOBIC
(3E)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1
(3Z)-2-methyl-3-[[(5-methyl-1,3-thiazol-2-yl)amino]-oxidanyl-methylidene]-1,1-bis(oxidanylidene)-1$l^{6},2-benzothiazin-4-one
(3Z)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1
(3Z)-3-[hydroxy-[(5-methyl-2-thiazolyl)amino]methylidene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one
(E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide
1027136-06-6
125M387
133687-22-6
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide
3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1
3-[hydroxy-[(5-methylthiazol-2-yl)amino]methylene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one
3-{hydroxy[(5-methyl-1,3-thiazol-2-yl)amino]methylidene}-2-methyl-2,3-dihydro-4H-1,2-benzothiazin-4-one 1,1-dioxide
4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide
4-hydroxy-2-mehtyl-N-(5-mehtyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-Hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide
4-hydroxy-2-methyl-N-(5-methy-2-thiazolyl)-2H-1,2-benzothiazine-3-caboxamide-1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1?^{6},2-benzothiazine-3-carboxamide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l;{6},2-benzothiazine-3-carboxamide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide
4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazin-3-crboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide
71125-38-7
A837087
AB0007297
AB00383033_20
AB00383033-17
AB00383033-18
AB1009494
AC-1325
AC1L1HB1
AC1NQY12
AC1NTUST
AC1Q3XZW
AJ-63405
AK-77454
AKOS000279442
AKOS026749959
ALBB-027268
AN-15016
AN-668/13244001
ANW-57553
Apo-meloxicam
BB_SC-04648
BBL029076
BC200593
BDBM50056998
BG0248
BIDD:GT0726
Bio-0826
BSPBio_002257
C-20653
C08169
C14H13N3O4S2
CAS-71125-38-7
CC-30198
CCG-39098
CCRIS 9139
CHEBI:6741
CHEMBL1741042
CHEMBL599
Co Meloxicam
Coxflam
Coxicam
CPD000718800
CS-2247
CTK6C3599
CTK6C3600
D00969
D0G7FJ
DB00814
Dom-meloxicam
DR001780
DSSTox_CID_803
DSSTox_GSID_20803
DSSTox_RID_75796
DTXSID1020803
EN300-52507
ETI-511
F2173-0387
FT-0082769
FT-0628193
Gen-meloxicam
GTPL7220
HE382281
HMS1922D19
HMS2089B18
HMS2096I19
HMS2234P07
HMS2236C09
HMS3259H06
HMS3372C13
HMS3372P18
HMS3655K06
HSCI1_000045
HSDB 7741
HY-B0261
I06-0490
J10218
KB-242264
KBio2_002113
KBio2_004681
KBio2_007249
KBio3_001477
KBioGR_001234
KBioSS_002113
KS-00000JN4
KS-1084
Lopac0_000766
LS-40538
M1959
MCULE-4138373089
Melonex
meloxicam
Meloxicam 5g
Meloxicam (JAN/USAN/INN)
Meloxicam (Mobic)
Meloxicam (SoluMatrix/arthritis)
Meloxicam (SoluMatrix/arthritis), iCeutica
Meloxicam [USAN:BAN:INN]
Meloxicam [USAN:USP:INN:BAN]
Meloxicam 1.0 mg/ml in Dimethyl Sulfoxide
Meloxicam nanoformulation capsules (arthritis), iCeutica
meloxicam sodium hydrate
Meloxicamum
Meloxicamum [Latin]
Meloxivet
Metacam
MFCD00868752
miloxicam
MLS000028587
MLS001304725
MLS001306413
MLS006011422
Mobec
Mobic (TN)
Mobicox
MolPort-002-885-839
Movalis
Movatec
MXM
N-1539
NC00698
NCGC00018248-01
NCGC00018248-02
NCGC00018248-03
NCGC00018248-04
NCGC00018248-05
NCGC00018248-06
NCGC00018248-08
NCGC00022924-03
NCGC00022924-04
NCGC00256316-01
NCGC00259238-01
NCGC00263878-02
Novo-meloxicam
Opera_ID_2
Parocin
PHL-meloxicam
PMS-meloxicam
R3928
Ratio-meloxicam
reumoxicam
Revmoksikam
RTR-031220
s1734
SAM002589991
SC-12165
SCHEMBL33369
SCHEMBL3576
SCHEMBL713100
SMP2_000133
SMR000058994
SMR000718800
SPBio_000902
Spectrum_001633
SPECTRUM1504150
Spectrum2_000941
Spectrum3_000649
Spectrum4_000787
Spectrum5_001813
ST24023559
STK620505
Tenaron
TL8005001
Tox21_111734
Tox21_111734_1
Tox21_113192
Tox21_201689
Tox21_302756
UH-AC 62XX
UHAC-62XX
UNII-VG2QF83CGL
VG2QF83CGL
Vivlodex
Z1695493323
ZINC103620661
ZINC13129998
ZRVUJXDFFKFLMG-UHFFFAOYSA-N
ZX-AN025777

US Patents and Regulatory Information for MOBIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim MOBIC meloxicam SUSPENSION;ORAL 021530-001 Jun 1, 2004 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Boehringer Ingelheim MOBIC meloxicam TABLET;ORAL 020938-001 Apr 13, 2000 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim MOBIC meloxicam TABLET;ORAL 020938-002 Aug 23, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for MOBIC
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Oral Suspension 7.5 mg/5 mL ➤ Subscribe 2009-12-17

Non-Orange Book US Patents for MOBIC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,682,747 Process for preparing an oral suspension of a pharmaceutical substance ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Julphar
Harvard Business School
Fuji
Teva
Baxter
Fish and Richardson
AstraZeneca
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.